Loading
Life sciences · Journal article
Meditsinskiy Sovet = Medical Council · October 10, 2026
No summary has been generated for this record yet. What follows is drawn from its source metadata only.
Journal article.
No findings were extractable from the material analysed.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
The source did not state who this applies to in practice.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
This record has not been graded across any dimension yet. Treat the label above as provisional and read the source.
What is missing. This record has no bottom line, key findings, reported figures, evidence dimensions. That is a gap in the analysis, not a judgement about the study.
Understanding the physiology of the incretin system is critically important for the safe and effective use of medications that modulate this system – GLP-1 receptor agonists (liraglutide, semaglutide) and a dual GLP-1 and GIP receptor agonist (tirzepatide) in weight-correction programs with a cosmetic purpose. Tirzepatide demonstrates higher efficacy in reducing body weight compared to GLP-1 monoagonists.The available data on the positive effect of the dual agonist (Sejaro®) on metabolic processes demonstrate its enormous therapeutic potential as a drug of choice for obesity and hyperglycemia. Due to their effect on the regulation of digestive system function, the most common side effects of incretin system modulators are gastrointestinal disorders (nausea, vomiting, diarrhea, constipation), which are caused by a slowdown in gastroduodenal motility and adaptation of the gastrointestinal tract to reduced food intake. These effects can lead to loss of skin turgor, the formation of striae, and atrophy of the subcutaneous fatty tissue in the facial area (Ozempic face) as a result of nutrient deficiency, reduced synthesis of collagen and elastin, and redistribution of soft tissue volume. In this regard, the prevention of cosmetic complications during weight loss using incretin system modulators, particularly tirzepatide, should include gradual titration of the drug dose, small-portion nutrition, and monitoring of skin condition dynamics. All therapeutic and preventive measures should be carried out within the framework of interdisciplinary collaboration between an endocrinologist, a dietitian, a cosmetologist, a plastic surgeon, and other specialists. A differentiated approach using incretin-based medications, particularly dual GLP-1 and GIP receptor agonists (tirzepatide, Sejaro®), given their highest efficacy, will make it possible to achieve targeted weight loss results, minimize aesthetic complications, increase patients’ satisfaction with treatment outcomes, and ensure long-term adherence to therapy. In this review we summarized the scientific evidence from 52 domestic and foreign medical periodicals.